Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Exosomes and Liquid Biopsies Asia 2016

Exosomes and Liquid Biopsies Asia 2016 Agenda


Print Agenda

Thursday, 7 April 2016

07:45

Conference Registration, Coffee, Tea and Breakfast Pastries in the Exhibit Hall

08:30

Tsai-Kun LiKeynote Presentation

Conference Opens and Welcoming Speech by Associate Dean of National Taiwan University
Tsai-Kun Li, Associate Dean & Professor, National Taiwan University College of Medicine; Chief Executive Officer, Center for Genomic Medicine, National Taiwan University, Taiwan


Session Title: Liquid Biopsies for Cancer and Beyond


Session Chairman: Dominique de Kleijn, Ph.D.

08:45

Introduction to the Field and Framing the Challenges in the Study of Exosomes and Various Classes of Circulating Biomarkers
Dominique PV de Kleijn, Professor Experimental Vascular Surgery, Professor Netherlands Heart Institute, University Medical Center Utrecht, The Netherlands, Netherlands

09:00

John PalmaKeynote Presentation

Clinical Performance of Liquid Biopsy Based Detection of EGFR Mutations in NSCLC
John Palma, Chief Medical Officer, Roche Sequencing Solutions, United States of America

09:30

Dominique PV de KleijnKeynote Presentation

Plasma Extracellular Vesicle Content for Diagnosis and Prognosis of Cardiovascular Disease
Dominique PV de Kleijn, Professor Experimental Vascular Surgery, Professor Netherlands Heart Institute, University Medical Center Utrecht, The Netherlands, Netherlands

Cardiovascular Disease (CVD) is with the cardiovascular events of Ischemic Heart Disease and Stroke, the number 1 and 2 cause of death in the world and expect to increase especially in Asia. Atherosclerosis is the underlying syndrome for CVD and atherosclerotic plaques are detectable already in teenagers. Therefore for cardiovascular disease, we have to determine who is at high risk for a cardiovascular event in a high-risk background of the atherosclerotic syndrome without the possibility of taking a plaque biopsy. The risk for Cardiovascular events is region-dependent so tailored plasma-based biomarkers are essential to guide prevention and treatment of billions. Collecting plasma extracellular vesicles is like taking a liquid biopsy from the pathological tissue that can be used for diagnosis and prognosis of the disease. We show that plasma extracellular vesicle protein content especially when collected from different plasma subfractions can be used as an accurate source for diagnosis and prognosis of cardiovascular disease.

10:00

Steve SoperKeynote Presentation

Integrated Microfluidic Systems for the Isolation of CTCs, cfDNA and Exosomes
Steve Soper, Foundation Distinguished Professor, Director, Center of BioModular Multi-scale System for Precision Medicine, The University of Kansas, Adjunct Professor, Ulsan National Institute of Science & Technology, United States of America

10:30

Coffee and Tea Break, Meet the Exhibitors and Networking

11:15

Danilo TagleKeynote Presentation

The NIH Extracellular RNA Communication Program: exRNA for Therapy and Biomarker Development
Danilo Tagle, Associate Director For Special Initiatives, Office of the Director, National Center for Advancing Translational Sciences at the NIH (NCATS), United States of America

Extracellular RNA (exRNA) can act as an endocrine signal to alter the phenotypes of target cells, and represents a novel paradigm in intercellular signaling. RNAseq analyses have identified a diverse population of exRNA that have been linked to regulation of the epigenome which could have profound implications for a wide range of physiologic and pathologic processes. The NIH Extracellular RNA Communication program supports research in exRNA-based biomarker and therapy development, as well as understanding fundamental principles of their biogenesis, distribution, uptake and function.

11:45

A Complete Next-Generation Sequencing Workflow for Circulating DNA Isolation and Analysis
Xingwang Fang, Senior Staff Scientist, Thermo Fisher Scientific, United States of America

Circulating cell-free DNA (cfDNA) has been shown to have potential as a non-invasive substrate for the detection and progression of tumor cells. As circulating tumor DNA is often present at low frequencies within cfDNA, targeted sequencing is an optimal tool for mutation detection.  To support advancement of cfDNA research, we have developed MagMAXTM Cell-free DNA Isolation kit to efficiently isolate and enrich cfDNA and Ion AmpliSeqTM technology to analyze rare mutation with deep sequencing.

12:15

Taiwanese-Style Buffet Lunch and Networking


Session Title: Circulating Tumor Cells (CTCs) and Other Circulating Biomarker Classes for Liquid Biopsies Studied via Microfluidics and Chips

13:30

Hsian-Rong TsengKeynote Presentation

NanoVelcro-Embedded Microchips for Detection and Characterization of Circulating Tumor Cells
Hsian-Rong Tseng, Professor, Crump Institute for Molecular Imaging, California NanoSystems Institute, University of California-Los Angeles, United States of America

Inspired by the nanoscale interactions observed in the tissue microenvironment, our research team at UCLA pioneered a unique concept of “NanoVelcro” cell-affinity substrates, in which CTC capture agent-coated nanostructured substrates were utilized to immobilize CTCs with high efficiency. The working mechanism of NanoVelcro cell-affinity substrates mimics that of VelcroTM – when the two fabric strips of a Velcro fastener are pressed together, tangling between the hairy surfaces on two strips leads to strong binding.  Through continuous evolution, 3 generations of NanoVelcro CTC Chips have been established to achieve different clinical utilities. My presentation will summarize the continuous evolution of NanoVelcro CTC Assays from the emerge of the original idea all the way to their applications in cancer research and diagnosis. We envision that NanoVelcro CTC Assays will lead the way for powerful and cost-efficient diagnostic platforms for researchers to better understand underlying disease mechanisms and for physicians to monitor real-time disease progression.

14:00

SACA Chip for Rapid Circulating Tumor Cells Diagnostics
Fan-Gang Tseng, Distinguished Professor, National Tsing-Hua University, Taiwan

Despite the recent advancement of biotechnology and pharmaceutical research, cancers remain the leading cause of human mortality. It is vital to diagnose cancers at an early stage when treatment can dramatically improve prognosis. So far, low-cost and easy to operate devices, which allow efficient isolation and sensitive detection of circulating tumor cells (CTCs) for routine blood screening, remain lacking. This talk will introduce a novel micro fluidic platform which can isolate CTCs from the real blood sample in 30 minutes: this system includes a high throughput blood cell separation chip which can separate white blood cells with CTCs from red blood cells and platelets by inertial and suction actions; a nano structured surface which can allow higher retention rate of CTCs on the surface for sample enrichment by 100 folds from 1/107 upto 1/105 CTCs/WBCs and the enriched sample will go through a final cells self-assembly process into a densed monolayer on a cell assembly chip for in parallel inspection at high speed.  As a result, the CTCs can be identified in 30 minutes by the integration of these three chips altogether.  Isolated CTCs will still be in vital and can be further characterized and cultivated for the identification of cancer stem cells for prognosis.

14:30

Microfluidic Capture, Identification, and Isolation of EMT-transformed Cancer Stem Cells
Wilber Huang, Chairman, Abnova, Taiwan

Persistence of cancer stem cells (CSCs) prevents effective therapy of tumors. Epithelial mesenchymal transition (EMT) of CSCs provides the engine of plasticity for breaking CSC dormancy causing tumor relapse and metastasis.  Current isolation of CSCs relies on magnetic beads-based, antibody selection to deplete the abundant CD45 cell fraction. This conventional negative enrichment is handicapped by lower cell capture and recovery, and without retrieval method for downstream cell culture.  Moreover, the detection of CSCs has been hampered by the lack of cancer- and mesenchymal-specific markers. Recent identification of cancer-specific EMT markers such as cytoplasmic Plastin-3 (PLS3) and Cell Surface Vimentin (CSV) has opened up this bottleneck for studies of EMT-transformed CSCs.  Both markers are not expressed by normal cells in the circulation.  Leveraging Abnova’s vertically integrated CytoQuest™ CR platform, we report the first microfluidic-based, antibody capture, identification, and retrieval of EMT-transformed CSCs. Such open platform should accelerate the research and clinical applications of EMT-transformed CSC for improved diagnosis and therapy for cancer patients.

15:00

Coffee and Tea Break and Networking in the Exhibit Hall

15:30

A Multifunctional qPCR Array for Large-Scale, Routine Analysis of Circulating Tumor Nucleic Acids (ctNAs)
Eric Yang, Quark Biosciences, Director of Application Development, Taiwan

microRNAs are increasing being recognized as a novel class of cancer molecular biomarkers with distinct advantages. Over the past decades, numerous publications have illustrated that microRNAs can be of diagnostic, prognostic and predictive values in the field of oncology. Utilizing PanelChip™, a qPCR array technology developed by Quark Biosciences, we’ve looked at the level of 160 microRNAs in the plasma of oral cancer patients before and after surgery. In addition, we’ve also examined the exosomal miRNAs of these patients. Preliminary result suggests that PanelChip™ can be of a powerful tool to screen and validate cell-free miRNA biomarkers for translational medical researchers. Combining the PanelChip™ platform with our on-going effort to build a cancer-based miRNA database, Quark Biosciences aims to become the leading solution provider for microRNA research.

16:00

Chwee Teck LimKeynote Presentation

Microfluidics for Liquid Biopsy & Personalized Medicine
Chwee Teck Lim, NUS Society Chair Professor, Department of Biomedical Engineering, Institute for Health Innovation & Technology (iHealthtech), Mechanobiology Institute, National University of Singapore, Singapore

Capturing of circulating Tumor Cells (CTCs) from the bloodstream of patients (a.k.a. liquid biopsy) may lead to better cancer detection and personalized medicine.  Using our developed microfluidic biochips, we not only showed successful detection and retrieval of CTCs, but also demonstrated how molecular analysis of each single CTC can enable personalized treatment by the detection of any actionable or druggable mutation.

16:30

Minetta LiuKeynote Presentation

Circulating Tumor Cells: The Promise and Reality of the Liquid Biopsy
Minetta Liu, Associate Professor and Chair, Oncology Research, Mayo Clinic, United States of America

The presentation objectives are as follows:  To discuss the potential impact of CTC molecular characterization in clinical practice. To review CTC isolation platforms in the context of demonstrating clinical utility as a liquid biopsy.

17:00

Close of Day 1 of the Conference

Friday, 8 April 2016

07:30

Breakfast in the Exhibit Hall, View Posters and Networking

08:00

Breakfast Briefing: The Patent Landscape of Precision Medicine in the USA: How Recent Court Decisions Will Affect this Rapidly Growing Field
Jorge Goldstein, Senior Director, Sterne Kessler Goldstein and Fox PLLC, United States of America

There have been dramatic legal changes in the USA on the patent eligibility of natural correlations (where a patent claim is drawn to a genetic diagnostic method of determining propensity to disease) and on the concept of "split infringement" (where two different parties, such as a clinical lab and a physician, each carry out one of a two-step patented process, such as detecting a mutation and then administering a personalized drug). These legal changes  have led to severe  problems with the patent protection and enforcement of precision medicine methods. We will discuss these legal developments and propose solutions.


Session Title: Exosomes and Extracellular Vesicles (EVs) -- Potential as Circulating Biomarkers for Liquid Biopsy Development


Session Chairman: David Wong, Ph.D.

08:30

Takahiro OchiyaKeynote Presentation

ExoScreen as a Novel Liquid Biopsy Platform for Detecting Cancer-Specific Exosomes
Takahiro Ochiya, Chief, National Cancer Center Research Institute Japan, Japan

A highly sensitive and rapid analytical technique for profiling circulating EVs/exosomes directly from blood samples of patients has also been established that uses two types of antibodies to capture two specific antigens residing on EVs and can be detected by photosensitizer beads. Using this system, higher signal detecting CD147 and CD9 double-positive EVs were observed in serum from colorectal cancer (CRC) patients compared with that in serum from healthy donors. A part of sera from CRC patients including stage I and II were positive for CD147, although both CEA and CA19-9 positive serum could not be found in those patients. On the basis of these results, this new ExoScreen technology may enable the effective diagnosis of cancer.

09:00

David WongKeynote Presentation

EFIRM Liquid Biopsy (eLB)
David Wong, Felix and Mildred Yip Endowed Chair in Dentistry; Director for UCLA Center for Oral/Head & Neck Oncology Research, University of California-Los Angeles, United States of America

The advent of personalized medicine employing molecular targeted therapies has markedly changed the treatment of cancer in the past 10 years. Although tumor tissue biopsy-based genotyping is the current clinical practice for guiding clinical management, biopsy procedures can result in significant morbidity, limiting sampling to static snapshots which are further limited in scope by the inherent sampling bias of the analysis itself. To overcome these issues, technologies are needed for rapid, cost-effective, and noninvasive identification of biomarkers at various time points during the course of disease. Liquid biopsy is a rapidly emerging field to address this unmet clinical need as diagnostics based on cell-free circulating tumor DNA (ctDNA) can be a surrogate for the entire tumor genome. The use of ctDNA via liquid biopsy will facilitate analysis of tumor genomics that is urgently needed for molecular targeted therapy. Currently, most targeted approaches are based on PCR and/or next generation sequencing (NGS) for liquid biopsy applications with performance concordance in the 60-80% range with biopsy-based genotyping. We have developed a liquid biopsy technology “Electric Field Induced Release and Measurement (EFIRM)- Liquid Biopsy (eLB)” provides the most accurate detection that can assist clinical treatment decisions for the most common subtype of lung cancer, non-small cell lung cancer (NSCLC), with tyrosine kinase inhibitors (TKI) that can extend the disease progress free survival period of these patients. eLB detects actionable EGFR mutations in NSCLC patients with 100% concordance with biopsy-based genotyping and outperforms current technologies (digital droplet PCR [ddPCR] and NGS) for liquid biopsy. eLB is minimally/ non-invasive, rapid, inexpensive and self-contained permitting the detection of the most common EGFR gene mutations that are treatable with TKI such as Gefitinib or Erlotinib to effectively extend the progression free survival of lung cancer p

09:30

Daniel ChiuKeynote Presentation

Rare Cell Diagnostics
Daniel Chiu, A. Bruce Montgomery Professor of Chemistry, University of Washington, United States of America

This presentation will describe advances we have made with the eDAR platform for the isolation of rare cells, with emphasis on employing eDAR for the analysis of circulating tumor cells.

10:00

Michael PfafflKeynote Presentation

Limitations and Challenges in MicroGenomics -- What we can Learn from Single-Cell and Exosome Expression Profiling
Michael Pfaffl, Professor, Technical University of Munich, Germany

So far quantitative real-time RT-PCR is the ‘Gold standard’ in molecular and clinical diagnostics, due to its high sensitivity, good reproducibility, and the wide dynamic quantification range. It is the most sensitive method for the quantification of mRNA/microRNA expression levels, in particular for extreme low abundant transcripts in tissue samples or liquid biopsies with limited RNA concentrations, e.g. single-cells, microvesicles or exosomes. Today the identification of novel and valid ‘biomarker signatures’ are in the focus. Therefore RNA Sequencing is increasingly used in experimental and clinical samples, to get the ‘holistic view’ on the mRNA and small RNA transcriptome.

10:30

Coffee and Tea Break and Networking in the Exhibit Hall

11:15

Tumor Exosomes in Organotropic Metastasis
Tang-Long Shen, Professor, National Taiwan University, Taiwan

As proposed by Stephen Paget in 1889, the “ seed and soil” hypothesis implicates an organotropic metastasis in cancers. To resolve the specificity of organotropism, we have determined that tumor exosomal integrins are key determinants for guiding organotropic targeting and the sequential Src phosphorylation and pro-inflammatory S100 gene expression happens in the recipient cell. Therefore, a pre-metastatic niche is created for subsequent cancer metastasis. Blocking of exosomal integrins, such as a6ß4 and a6ß1 were associated with lung metastasis, impaired lung metastasis. Together, these data indicate tumor exosomes may be used for prediction and therapeutic targets of cancer metastasis.

11:45

From Sample to Insight: Integrated Solutions for Liquid Biopsy – Rapid Isolation of Exosomes, Other Extracellular Vesicles and Vesicular RNA
Martin Schlumpberger, Associate Director, Scientific Applications, QIAGEN, Germany

Liquid Biopsy has the potential to transform healthcare and biomedical research. The presentation will give an overview on QIAGEN’s approach to provide integrated solutions for isolation of circulating biomarkers and their analysis in research and diagnostic applications. For isolation and analysis of exosomal RNA and other exosomal content a new affinity-based spin column procedure is presented. It allows separation of vesicular RNA (incl. intact mRNA transcripts and miRNA) from non-vesicular RNA. The same approach can also be applied to rapid isolation of intact exosomes and other extracellular vesicles (EVs) for physical characterization, analysis of vesicular proteins, and functional studies.

12:15

Taiwanese-Style Buffet Lunch and Networking

13:00

iZON Science Ltd.Technology Spotlight:
Application of SEC and TRPS in isolation and quantification of EVs
Ian Yan, Application Scientist, iZON Science Ltd.

Accurate concentration, size and charge of exosome in biological fluid have been analysized by using size-exclusion chromatography (SEC) and tunable resistive pulse sensing (TRPS) technology.


Session Title: Circulating Cell-Free DNA (cfDNA) for Developing Liquid Biopsies -- Technologies and Approaches

13:30

Sehyun ShinKeynote Presentation

Multiplexed Detection of Circulating Tumor DNA using Microfluidic Surface Plasmon Resonance (SPR) Sensormetry
Sehyun Shin, Professor & Director, Nano-Biofluignostic Engineering Research Center, Korea University and Anam/Guro Hospital of Korea University, Korea South

Circulating tumor DNA (ctDNA) has been demonstrated as the most promising biomarker for non-invasive assessment of cancer as well as the most accurate predictor of cancer treatment responses. However, detection of ctDNA in blood has been faced with conventional technical limits and called for innovative technologies and methods.
Here, we present a stable and selective assay for multiplexing detection of epidermal growth factor receptor (EGFR) mutation of most common mutations in plasma using DNA-DNA hybridization and selective linker prove with a lab-made surface plasmon resonance (SPR) sensometry. We prepared wild type and mutant templates of E746-A750 deletion in exon 19. Linker DNAs coated on a sensor surface of SPR capture different quantities of two different DNA types. Due to characteristics of SPR, the whole process was monitored in real-time and completed within an hour. Quantification data of SPR was compared with result of peptide nucleic acid (PNA) – locked nucleic acid (LNA) clamping PCR method for EGFR mutation detection. This study as a proof of concept can be further expanded into multiplexing detection of major and known ctDNAs, which could provide a solution for clinical unmet needs in cancer treatment and early detection.

14:00

Paper-based Devices for Isolation and Characterization of Extracellular Vesicles and Clinical Applications
Chao-Min Cheng, Associate Professor, National Tsing Hua University, Taiwan

We have developed a paper-based immunoaffinity platform for separating subgroups of EVs that is easy, efficient, and requires sample volumes as low as 10 µL. Biological samples can be pipetted directly onto paper test zones that have been chemically modified with capture molecules that have high affinity to specific EV surface markers. We have validated the assay by using different approaches such as scanning electron microscopy (SEM), paper-based enzyme-linked immunosorbent assays (P-ELISA), and transcriptome analysis. These paper-based devices would enable the study of EVs in the clinic, what we will mention in the talk as well, and the research setting to help advance our understanding of EV functions in health and disease.

14:30

Michael FreemanKeynote Presentation

The Amoeboid Tumor Phenotype and Mechanisms of Tumor Migration and Conditioning of the Tumor Microenvironment
Michael Freeman, Vice Chair of Research, Director, Cancer Biology and Therapeutics, Cedars-Sinai Medical Center, United States of America

15:00

Coffee and Tea Break -- Networking with the Exhibitors

15:30

The Journey to Human Follicular Maturation: The Story as told by Exosomes
Shlomit Kenigsberg, Senior Researcher, Create Fertility Centre, Canada

Extracellular vesicles (EVs), including exosomes (60-180nm), are actively secreted by cells and tissues and have been described and characterized in all body fluids tested so far, including semen, CSF, synovial fluid, etc. They contain distinct subsets of DNA, RNAs, proteins and lipids, and are ideal non-invasive diagnostic biomarkers because they represent cell-derived signals. Follicular fluid (FF) provides part of the microenvironment that regulates oocyte development and thus, may play a critical role in oocyte fertilization and embryo development. Intercellular signaling between granulosa cells (GLC), cumulus cells (CM), and the oocyte is required for proper folliculogenesis, ovulation, and hormonal secretion. These signals can be mediated by extracellular vesicles (EVs), such as exosomes. We applied multiple approaches to isolate and characterize and visualized EVs in FF (FFEs), that will be discuss in my talk. I will also discuss their potential as biomarkers for ovarian reserve and egg quality.

16:00

Fred KramerKeynote Presentation

Closing Keynote: Multiplex Detection of Extremely Rare Mutant Sequences Associated with Cancer
Fred Kramer, Professor of Microbiology, Biochemistry & Molecular Genetics, New Jersey Medical School Rutgers University, United States of America

Extraordinarily specific “SuperSelective” PCR primers enable the simultaneous quantitation of extremely rare mutations that occur in different cells, even though they are located within the same or adjacent codons.  Consequently, multiplex assays for the early detection of mutations associated with cancer should enable therapy to be guided by the results of periodic “liquid biopsies” that analyze DNA fragments present in plasma samples.

17:00

Close of Conference


Add to Calendar ▼2016-04-07 00:00:002016-04-08 00:00:00Europe/LondonExosomes and Liquid Biopsies Asia 2016Exosomes and Liquid Biopsies Asia 2016 in Taipei, TaiwanTaipei, TaiwanSELECTBIOenquiries@selectbiosciences.com